GSK plc (GSK,GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended for use a single-vial, fully liquid presentation of Menveo to help protect against invasive meningococcal disease caused by bacterial groups A, C, W, and Y. The Group said the positive opinion marks one of the final steps prior to the potential extension of the marketing authorisation by the European Commission. The final decision is expected by November 2024.
If approved, the single-vial presentation will be licenced for active immunisation of children from 2 years of age, adolescents and adults. The MenACWY vaccine has received regulatory approval in over 60 countries, with more than 82 million doses distributed worldwide since 2010.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.